



We claim:


1. A compound of the general formula (I),



5 or their stereoisomers and pharmaceutically acceptable salts thereof,
wherein,



X is halogen or hydrogen;



10

“~~~~~” is point of attachment;

15

“-----” is bond or no bond;


R₁ is hydrogen, fluorine or hydroxyl;

R₂ is hydrogen or fluorine; provided that R₂ is fluorine when “-----” is no bond;


and

“n” is 1 or 2.

2. The compound according to claim 1, wherein:



X is chlorine, bromine or hydrogen;




“~” is point of attachment; and

R₁ is hydrogen.


3. The compound according to claim 1, wherein the compound is selected from,

(a) a compound of formula **(Ib-1)**:



or their stereoisomers and pharmaceutically acceptable salts thereof,


wherein,




“~” is point of attachment;

X is chlorine;

(b) a compound of formula **(Ib-2)**:




or their stereoisomers and pharmaceutically acceptable salts thereof,
wherein,




5 X is chlorine;
“~~~~~” is point of attachment;

(c) a compound of formula **(Id-1)**:




10 or their stereoisomers and pharmaceutically acceptable salts thereof,
wherein,
“-----” is a bond or no bond;




15 X is chlorine or bromine;
“~~~~~” is point of attachment;
R₂ is hydrogen or fluorine; provided that R₂ is fluorine when “-----” is no bond;

(d) a compound of formula **(Id-2)**:



or their stereoisomers and pharmaceutically acceptable salts thereof,
wherein,

“-----” is a bond or no bond;




X is chlorine;


“~~~~~” is point of attachment;

R₂ is hydrogen or fluorine; provided that R₂ is fluorine when “-----” is no bond;

10 (e) a compound of formula **(Ie-1)**:




or their stereoisomers and pharmaceutically acceptable salts thereof,
wherein,



X is chlorine;


“~~~~~” is point of attachment;

(f) a compound of formula **(Ie-2)**:



or their stereoisomers and pharmaceutically acceptable salts thereof,


“-----” is a bond or no bond;




5 X is chlorine;

“~~~~~” is point of attachment; and

(g) a compound of formula **(If-1)**:



10 or their stereoisomers and pharmaceutically acceptable salts thereof,
wherein,



X is chlorine or bromine;

R₂ is hydrogen or fluorine;

15 “n” is 1 or 2.

4. The compound according to claim 1, which is selected from the group consisting of:
5-Amino-6-chloro-N-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide hydrochloride;

- 5-Amino-6-chloro-*N*-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide hemifumarate;
- 5-Amino-6-chloro-*N*-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide L(+)-tartarate;
- 5 5-Amino-6-chloro-*N*-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide;
- 5-Amino-6-chloro-*N*-{[3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide;
- 10 5-Amino-6-chloro-*N*-{[3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide L(+)-tartarate;
- 5-Amino-*N*-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide L(+)-tartarate;
- 5-Amino-*N*-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide;
- 15 (R,S) 5-Amino-6-chloro-*N*-{[3-(tetrahydro-3-furanylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide;
- (R,S) 5-Amino-6-chloro-*N*-{[3-(tetrahydro-3-furanylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide L(+)-tartarate;
- 5-Amino-6-bromo-*N*-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide;
- 20 5-Amino-6-bromo-*N*-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide L(+)-tartarate;
- 4-Amino-5-chloro-*N*-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide;
- 25 4-Amino-5-chloro-*N*-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide hydrochloride;
- 4-Amino-5-chloro-*N*-{[3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide;
- 4-Amino-5-chloro-*N*-{[3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide oxalate;
- 30 4-Amino-5-chloro-*N*-{[3-(1-methoxycarbonylpiperidine-4-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide;

- 4-Amino-5-chloro-*N*-{[3-(1-methoxycarbonylpiperidine-4-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide oxalate;
- 4-Amino-5-chloro-2-methyl-*N*-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide;
- 5 4-Amino-5-chloro-2-methyl-*N*-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide hydrochloride;
- 4-Amino-5-chloro-*N*-[(3-isopropyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2,3-dihydrobenzofuran-7-carboxamide;
- 4-Amino-5-chloro-*N*-[(3-isopropyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2,3-dihydrobenzofuran-7-carboxamide oxalate;
- 10 4-Amino-5-chloro-*N*-{[3-(cyclobutylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2,3-dihydrobenzofuran-7-carboxamide;
- 4-Amino-5-chloro-*N*-{[3-(cyclobutylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2,3-dihydrobenzofuran-7-carboxamide oxalate;
- 15 4-Amino-5-chloro-*N*-{[3-(1-methoxycarbonylpiperidine-4-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2,3-dihydrobenzofuran-7-carboxamide;
- 4-Amino-5-chloro-*N*-{[3-(1-methoxycarbonylpiperidine-4-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2,3-dihydrobenzofuran-7-carboxamide L(+)-tartarate;
- 4-Amino-5-chloro-*N*-{[3-(tetrahydropyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2,3-dihydrobenzofuran-7-carboxamide;
- 20 4-Amino-5-chloro-*N*-{[3-(tetrahydropyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2,3-dihydrobenzofuran-7-carboxamide L(+)-tartarate;
- 4-Amino-5-chloro-*N*-{[3-(tetrahydropyran-4-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2,3-dihydrobenzofuran-7-carboxamide;
- 25 4-Amino-5-chloro-*N*-{[3-(tetrahydropyran-4-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2,3-dihydrobenzofuran-7-carboxamide oxalate;
- 4-Amino-5-bromo-*N*-{[3-(tetrahydropyran-4-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2,3-dihydrobenzofuran-7-carboxamide;
- 4-Amino-5-bromo-*N*-{[3-(tetrahydropyran-4-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2,3-dihydrobenzofuran-7-carboxamide oxalate;
- 30 5-Amino-6-chloro-*N*-{[3-(4-hydroxytetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide;

- 5-Amino-6-chloro-*N*-{[3-(4-hydroxytetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide L(+)-tartarate;
- 4-Amino-5-chloro-*N*-{[3-(4-hydroxytetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide;
- 5 4-Amino-5-chloro-*N*-{[3-(4-hydroxytetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide oxalate;
- 4-Amino-5-chloro-*N*-{[3-(4-hydroxytetrahydropyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2,3-dihydrobenzofuran-7-carboxamide;
- 4-Amino-5-chloro-*N*-{[3-(4-hydroxytetrahydropyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2,3-dihydrobenzofuran-7-carboxamide oxalate;
- 10 5-Amino-6-chloro-*N*-{[3-(4-fluorotetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl] methyl}chroman-8-carboxamide;
- 5-Amino-6-chloro-*N*-{[3-(4-fluorotetrahydro-2H-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl] methyl}chroman-8-carboxamide L(+)-tartarate;
- 15 5-Amino-6-chloro-*N*-{[3-(2-hydroxy-2-methyl propyl)-3-azabicyclo[3.1.0]hex-6-yl] methyl}chroman-8-carboxamide;
- 5-Amino-6-chloro-*N*-{[3-(2-hydroxy-2-methyl propyl)-3-azabicyclo[3.1.0]hex-6-yl] methyl}chroman-8-carboxamide L(+)-tartarate;
- 4-Amino-5-chloro-*N*-{[4-fluoro-1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl}benzofuran-7-carboxamide;
- 20 4-Amino-5-chloro-*N*-{[4-fluoro-1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl}benzofuran-7-carboxamide hydrochloride;
- 4-Amino-5-chloro-*N*-{[3-(2-hydroxy-2-methylpropyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2,3-dihydrobenzofuran-7-carboxamide;
- 25 4-Amino-5-chloro-*N*-{[3-(2-hydroxy-2-methylpropyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2,3-dihydrobenzofuran-7-carboxamide oxalate;
- 5-Amino-6-chloro-*N*-{[4-fluoro-1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl}chroman-8-carboxamide;
- 5-Amino-6-chloro-*N*-{[4-fluoro-1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl}chroman-8-carboxamide L(+)-tartarate;
- 30 5-Amino-6-bromo-*N*-{[4-fluoro-1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl}chroman-8-carboxamide;

- 5-Amino-6-bromo-*N*-{[4-fluoro-1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl}chroman-8-carboxamide L(+)-tartarate;
- 4-Amino-5-chloro-*N*-{[4-fluoro-1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl}benzofuran-7-carboxamide L(+)-tartarate;
- 5 4-Amino-5-chloro-*N*-{[3-(2-hydroxy-2-methyl propyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide;
- 4-Amino-5-chloro-*N*-{[3-(2-hydroxy-2-methyl propyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide L(+)-tartarate;
- 4-Amino-5-chloro-2-methyl-*N*-{[1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl}benzofuran-7-carboxamide;
- 10 4-Amino-5-chloro-2-methyl-*N*-{[4-fluoro-1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl}benzofuran-7-carboxamide;
- 4-Amino-5-chloro-2-methyl-*N*-{[4-fluoro-1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl}benzofuran-7-carboxamide L(+)-tartarate;
- 15 4-Amino-5-chloro-2-methyl-*N*-{[3-(2-hydroxy-2-methyl propyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide;
- 5-Amino-6-chloro-*N*-{[1-(2-fluoro-2-methyl propyl)-4-fluoro-4-piperidinyl]methyl}chroman-8-carboxamide;
- 5-Amino-6-chloro-*N*-{[1-(2-fluoro-2-methyl propyl)-4-fluoro-4-piperidinyl]methyl}chroman-8-carboxamide L(+)-tartarate;
- 20 5-Amino-6-chloro-*N*-{[3-(3-hydroxy-2,2-dimethyl propyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide;
- 5-Amino-6-chloro-*N*-{[3-(3-hydroxy-2,2-dimethyl propyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide L(+)-tartarate;
- 25 5-Amino-6-chloro-*N*-{[3-(3-methoxy-2,2-dimethyl propyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}chroman-8-carboxamide;
- 4-Amino-5-chloro-*N*-{[3-(3-methoxypropyl)-3-azabicyclo[3.1.0]hex-6-yl] methyl}-2,3-dihydrobenzofuran-7-carboxamide;
- 4-Amino-5-chloro-*N*-{[3-(3-methoxypropyl)-3-azabicyclo[3.1.0]hex-6-yl] methyl}-2,3-dihydrobenzofuran-7-carboxamide oxalate;
- 30 4-Amino-5-chloro-*N*-{[3-(3-methoxy propyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide;

4-Amino-5-chloro-*N*-{[3-(3-methoxy propyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide hydrochloride;

4-Amino-5-chloro-2-methyl-*N*-{[3-(3-methoxy propyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide;

5 4-Amino-5-chloro-2-methyl-*N*-{[3-(3-methoxy propyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzofuran-7-carboxamide hydrochloride;and

4-Amino-5-bromo-*N*-{[3-(3-methoxypropyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2,3-dihydrobenzofuran-7-carboxamide oxalate.

10 5. A pharmaceutical composition comprising the compound according to any of the claims 1 to 4, and pharmaceutically acceptable excipients or carriers.

6. The pharmaceutical composition according to claim 5, for use in the treatment of disorder related to 5-HT₄ receptor such as Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder, Huntington's disease, Parkinson's disease, depression or psychiatric disorders.

7. Use of the compound according to any one of the claims 1 to 4, for the manufacture of medicament for the treatment of disorders related to 5-HT₄ receptor selected from the group consisting of Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder, Huntington's disease, Parkinson's disease, depression and psychiatric disorders.

8. The compound according to any one of the claims 1 to 4, for use in the treatment of various disorders selected from Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder, Huntington's disease, Parkinson's disease, depression and psychiatric disorders.